Growing US Presence Onyx Scientific is actively expanding commercial operations in the United States, evidenced by the appointment of a North America Business Development Manager to drive growth. This presents an opportunity to propose US-facing manufacturing partnerships, CDMO services for late-stage development, and potential co-development deals with pharma clients seeking US-scale API production.

UK India Scale With licensed UK and India sites and internal tech transfer capabilities, Onyx can offer end-to-end manufacturing solutions from discovery chemistry through GMP API production and scalable tech transfer. A compelling angle is offering seamless scale-up packages and supply chain resilience for global clients seeking diversified manufacturing footprints.

Specialist Capabilities The UK labs focus on complex chemistry, lead optimization, solid-state chemistry, and GMP API synthesis, enabling Onyx to target early-to-mid phase programs and custom synthesis needs. Sales opportunities exist in partnering for niche small-molecule programs requiring advanced chemistry and process development.

Growth Momentum Expanded Sunderland facilities in 2022 and ongoing commercial expansion indicate capacity ramp and modernization. This suggests readiness to absorb more programs, offer faster timelines, and pursue multi-site manufacturing contracts, including regional supply to Europe and North America.

Strategic Partnerships As a preferred partner to top global pharma and biotech clients, Onyx can be positioned for long-term CDMO partnerships, including early engagement in discovery-to-manufacturing cascades, tech transfer, and late-stage scale-up, appealing to firms seeking reliable, compliant, and scalable API production partners.